(Q37810562)

23 August 2017

Antibody therapy in neurodegenerative disease (English)

1 reference

23 August 2017

Antibody Therapy in Neurodegenerative Disease (English)

0 references

1 reference

1 reference

Amber L Southwell

1

1 reference

23 August 2017

Paul H Patterson

series ordinal

2

1 reference

23 August 2017

1 January 2010

1 reference

Reviews in the Neurosciences

23 August 2017

January 2010

0 references

published in

1 reference

23 August 2017

21

1 reference

23 August 2017

4

1 reference

23 August 2017

273-287

1 reference

The transcellular spread of cytosolic amyloids, prions, and prionoids

23 August 2017

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Amyloid-like features of polyglutamine aggregates and their assembly kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Protein misfolding inside cells: the case of huntingtin and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Parkinson's disease: mechanisms and models

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Conformational properties of alpha-synuclein in its free and lipid-associated states

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Detecting morphologically distinct oligomeric forms of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Huntingtin interacts with a family of WW domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Mechanisms underlying inflammation in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Intracellular pathways of folded and misfolded amyloid precursor protein degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Huntington's disease: from pathology and genetics to potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Intracellular antibodies (intrabodies) and their therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Autoantibodies to alpha-synuclein in inherited Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Nuclear targeting of mutant Huntingtin increases toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Degradation of beta-amyloid by proteolytic antibody light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Protective autoimmunity functions by intracranial immunosurveillance to support the mind: The missing link between health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FREVNEURO.2010.21.4.273

10.1515/REVNEURO.2010.21.4.273

21 January 2018

Identifiers

DOI

0 references

1 reference